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Background: Duchenne muscular dystrophy (DMD) is the most common X-linked muscle degenerative disease
and it is due to the absence of the cytoskeletal protein dystrophin. Currently there is no effective treatment for
DMD. Among the different strategies for achieving a functional recovery of the dystrophic muscle, the upregulation
of the dystrophin-related gene utrophin is becoming more and more feasible.
Results: We have previously shown that the zinc finger-based artificial transcriptional factor “Jazz” corrects the
dystrophic pathology in mdx mice by upregulating utrophin gene expression. Here we describe a novel artificial
transcription factor, named “UtroUp”, engineered to further improve the DNA-binding specificity. UtroUp has been
designed to recognise an extended DNA target sequence on both the human and mouse utrophin gene
promoters. The UtroUp DNA-binding domain contains six zinc finger motifs in tandem, which is able to recognise
an 18-base-pair DNA target sequence that statistically is present only once in the human genome. To achieve a
higher transcriptional activation, we coupled the UtroUp DNA-binding domain with the innovative transcriptional
activation domain, which was derived from the multivalent adaptor protein Che-1/AATF. We show that the artificial
transcription factor UtroUp, due to its six zinc finger tandem motif, possesses a low dissociation constant that is
consistent with a strong affinity/specificity toward its DNA-binding site. When expressed in mammalian cell lines,
UtroUp promotes utrophin transcription and efficiently accesses active chromatin promoting accumulation of the
acetylated form of histone H3 in the utrophin promoter locus.
Conclusions: This novel artificial molecule may represent an improved platform for the development of future
applications in DMD treatment.
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Duchenne Muscular Dystrophy (DMD) is the most com-
mon X-linked degenerative muscle disease. The diagnos-
tic marker for DMD is the absence of the cytoskeletal
protein dystrophin, which plays a major structural role in
muscle by providing stability to the sarcolemma during
muscle contractions [1]. DMD still lacks an effective cure;* Correspondence: nicoletta.corbi@libero.it
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reproduction in any medium, provided the oralthough different therapeutic strategies for DMD are cur-
rently being explored [2-6], a variety of drawbacks has sig-
nificantly delayed their clinical translation. A promising
approach for DMD therapy is based on increasing the
levels of utrophin, a cytoskeletal protein that is similar to
dystrophin and is able to compensate for its absence. Dys-
trophin and utrophin display a high degree of homology,
and both bind members of the dystrophin-associated pro-
tein complex (DAPC) [7]. In adult muscle, utrophin is
localised preferentially at the neuromuscular junction
(NMJ) and myotendinous junctions, while dystrophin istd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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However, utrophin is also found along the sarcolemma in
developing muscle, in regenerating muscle after injury and
in mdx (dystrophin-deficient) skeletal muscle [9]. In DMD
patients, utrophin is often upregulated, but this upregula-
tion is not sufficient to prevent the progression of muscular
dystrophy. Although the adenoviral delivery of utrophin in
the mouse model of DMD (mdx) and in the dystrophin-
deficient dog ameliorates the pathology, the huge size of
the utrophin gene is a critical disadvantage [10]. Therefore,
studies developing natural or synthetic small molecules that
upregulate utrophin could accelerate the clinical translation
process [11-17]. To obtain upregulation of utrophin, we
have engineered artificial zinc finger-based transcription
factors that are capable of binding and activating transcrip-
tion from promoter “A” of both the human and mouse
utrophin genes [18-23]. Zinc finger domains have been
shown to be optimal building blocks for generating artificial
transcription factors due to their versatility and modularity
[24,25]. In particular, a “recognition code” that relates the
amino acids of a single zinc finger to its associated DNA
target has been utilised as a guide for the DNA binding de-
sign [24-30]. Changes in the key amino acid positions (−1,
+3 and +6) of the zinc finger alpha-helix alter the DNA-
binding specificity of a zinc finger and enable it to bind the
programmed DNA-binding site [24]. We generated trans-
genic mice that specifically over-express an artificial three
zinc finger protein in the muscle, named “Jazz”, which is
able to specifically upregulate the utrophin gene [20].
Crossing the Jazz transgenic mice with the mouse Du-
chenne muscular dystrophy mouse model “mdx” results in
a strong amelioration of the dystrophic phenotype [22,23].
In a continued attempt to improve the artificial transcrip-
tion factor’s DNA-binding affinity/specificity, we engineered
“UtroUp” that recognises a longer DNA target sequence
than its prototype gene Jazz. UtroUp has been designed to
target the eighteen-base-pair DNA sequence present in
both human and mouse utrophin gene promoters “A”. This
target sequence is unique and conserved in both genomes.
Here, we show that the artificial transcription factor
UtroUp, due to its six zinc finger tandem motif, and its low
dissociation constant (Kd) possesses a strong affinity/speci-
ficity toward its DNA-binding site. UtroUp, coupled with
its activation domain that was derived from the adaptor
protein Che-1/AATF [21], efficiently accesses the active
chromatin in the utrophin promoter locus and strongly
activates utrophin transcription. This novel artificial mol-
ecule represents an improved platform for the develop-
ment of future applications in the DMD gene therapy field.
Methods
Constructs
The synthesis of the UtroUp gene was performed by
GenScript (New Jersey, USA). The company provided uswith the gene cloned into the pUC57 vector at the EcoRI
and XhoI restriction sites. We sub-cloned the synthetic
gene into pGEX-4T1 bacterial expression vector (GST-
UtroUp) and into the pRK5/myc mammalian expression
vector, under the control of cytomegalovirus regulatory
regions, in fusion with the CJ7 trans-activation domain
(CJ7-UtroUp) [21]. CJ7-Jazz molecule was cloned in the
same pRK5/myc mammalian expression vector. Note that
here, we simply referred to CJ7 as the activation domain,
which is one hundred amino acids long and strictly
derived from the human Che-1/AATF protein, and not as
the entire fusion protein that was described in our previ-
ous publication [21].
Expression of the bacterial recombinant fusion proteins
The recombinant GST-UtroUp protein and the recom-
binant GST-Jazz protein were expressed in BL21(DE3)
host bacteria by an IPTG induction and were purified
using glutathione Sepharose 4B beads as previously
described [18]. The GST fusion proteins were separated
by SDS-PAGE electrophoresis, visualized by Coomassie
blue staining and quantified.
Electrophoretic mobility shift assay (EMSA) and
dissociation constant
The EMSA were performed as previously described [18].
The oligonucleotide probes containing one copy of the
WT UtroUp DNA target (underlined) were the following:
forward primer 50-A TTA AGC CGG GCT GCT GCG
GGC TGG GAG TAT GAT CC-30 and reverse primer 50-
GG ATC ATA CTC CCA GCC CGC AGC AGC CCG
GCT TAA T-30. The mutagenized oligonucleotide probes
were: “Mutated” UtroUp forward primer 50-A TTA AGC
CGG GCT GCT taa taa TGG GAG TAT GAT CC-30 and
reverse primer 50-GG ATC ATA CTC CCA tta tta AGC
AGC CCG GCT TAA T-30; “Scrambled” UtroUp forward
primer 50-A TTA AGC CGG ACA ACC ATC GAT GTC
CGT TAT GAT CC-30 and reverse primer 50-GG ATC
ATA ACG GAC ATC GAT GGT TGT CCG GCT TAA
T-30. The oligos used in the EMSA were labelled by a T4
polynucleotide kinase. The binding buffer that was used
contained 20 mM Hepes pH 7.5, 0.5 mM DTT, 100 mM
NaCl, 50 μM ZnCl2, 50 μg/ml BSA, 100 ng of poly (dI-
dC), 0.05% NP40 and 5% glycerol. Percentage of both
inputs: WT and the “6 base pair” mutated DNA target
probes shifted at each protein concentration were quanti-
fied using ImageJ analysis software and plotted in a graph.
To measure and compare the apparent dissociation con-
stant (Kd) of the GST-UtroUp and GST-Jazz complexed
with their DNA-target, we performed a series of EMSA
with increasing amount of GST-UtroUp (1, 2, 3, 4, 8, 12,
30, 60 nM and 90 nM) or increasing amount of GST-Jazz
(5, 8, 16, 32, 64 and 96 nM) incubated with a constant
amount of labelled UtroUp-Jazz DNA target, following the
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active signals were visualised by autoradiography and
quantified by the ImageQuant software (Molecular Dy-
namics, Sunnyvale, CA) and the data were analysed with
the KaleidaGraph programme (Abelbeck Software, Read-
ing, PA). The Kd values were determined as an average of
data as mean ± S.D. of five separate experiments.
Cell lines, transient transfections and reporter gene assay
The human HeLa cell line was grown in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco Corporation,
Grand Island, NY, USA) supplemented with 10% foetal
calf serum. Transient transfection experiments in the
HeLa cell line were carried out using Lipofectin and
PLUS reagents (Life Technologies Corporation, Carlsbad,
Ca.) according to the manufacturer’s instructions. Cell
extracts were prepared and assayed for luciferase (LUC)
activity according to the manufacturer’s instructions (Pro-
mega, Madison, WI, USA) using a Berthold LB9506
luminometer. The total protein in the extracts was quan-
tified using a Bradford assay, and the LUC activity from
equal amounts of protein was determined and normalised
for beta-galactosidase activity.
Chromatin immunoprecipitation assay (ChIP)
Chromatin Immunoprecipitation was performed using a
ChIP assay kit according to the manufacturer’s instruc-
tions (Upstate Biotechnology, Charlottesville, VA, USA).
Approximately 8 million cells were cross-linked with 1%
formaldehyde for 10 min at 37°C and then lysed. The cell
lysate was sonicated on ice, which resulted in DNA frag-
ments of approximately 500 bp in length. Equal amounts
of chromatin from each sample were immunoprecipitated
over night with either an anti-acetylated-Histone H3
rabbit polyclonal antibody (Upstate Biotechnology) or
anti-myc 9E10 monoclonal antibody. DNA representing
0.005% of the sonicated chromatin solution (input) and
10% of the immunoprecipitated sonicated chromatin solu-
tion were amplified using the following primers: human
utrophin promoter region primers forward 50-CGGCA
CGCACGGTTCACTCTGGAGCGC-30 and reverse 50-
CAGCAACTTTGTTCCGGAAGATCAGCC-30; human
thymidine kinase promoter region–specific primers for-
ward 50-GCCCCTTTAAACTTGGTGGGCGG-30 and re-
verse 50-TTGCGCCTCCGGGAAGTTCACG-30; human
dystrophin promoter region–specific primers forward 50-
GTGTTTTAAGAATTGGCACCAG-30 and reverse 50-A
GTCTGAATAAGAGAAGCAGCA -30; human chromo-
some 16 region–specific primers forward 50-AGGACC
ACTCGCTGGGTAAGCA-30 and reverse 50-CGCGG
AGGGTGACATGGGGT-30; human chromosome 17
region–specific primers forward 50-ACCTGTGTGTGG
GTGGTGAGA-30 and reverse 50-CTGTAGGGCCCCA
GGCACCAT-30. The DNA sequence of the potential off-target site present in chromosome 16 is: 50-GCTGCT
GgGGGCTGGGgc-30, with 15/18 matches with UtroUp
target sequence. The DNA sequence of the potential off-
target present in chromosome 17 is: 50-GCTGCTGCG
GGCTGGGga-30, with 16/18 matches with UtroUp Tar-
get sequence. The PCR conditions were the following: 30
cycles at 95°C for 45 s, 62°C for 30 s, 72°C for 30 s and a
final extension at 72°C for 5 min. Quantification of each
chromatin immunoprecipitation (ChIP) experiment was
performed using ImageJ software and plotted in a graph.
RNA extraction, reverse transcriptase reaction and
real-time PCR
Total RNA was extracted from HeLa cells expressing ei-
ther CJ7-UtroUp or the negative control pRK5 using the
TRIzol reagent according to the manufacturer’s instruc-
tions (Life Technologies). Two μg of RNA was reverse
transcribed using oligo (dT)12–18 primers and Super-
script II (Life Technologies) in a final volume of 20 μl at
42°C for 50 min. A real-time PCR assay was performed
in a 96-well format using the ABI Prism 7000 Sequence
Detection System (Applied Biosystems, Foster City, CA).
Primers and probes for utrophin (target gene) and for
GAPDH (housekeeping gene) were purchased as Taq-
Man Gene Expression Assays (Applied Biosystems). PCR
mixtures containing the cDNA template, the TaqMan
Universal PCR master mix (Applied Biosystems) and the
primers/probes in a final volume of 25 μl were analysed
in triplicate using the following conditions: an incuba-
tion at 50°C for 2 min, denaturing at 95°C for 10 min
and then 40 cycles of the amplification step at 95°C for
15 s and 60°C for 1 min. For each gene amplification, a
standard curve was generated using serial dilutions (200,
40, 8, 1.6 and 0.32 ng) of cDNA from the HeLa cells
(negative control). The results were analysed using the
Applied Biosystems analysis software. The data are
expressed as the ratio between utrophin and GAPDH
mRNA expression.
Western blot
Proteins were extracted from HeLa cells using the fol-
lowing lysis buffer (50 mM Tris pH 7.4, 50 mM EDTA,
250 mM NaCl, 50 mM NaF, 0.1% Triton X-100, 0.1
mM NaVO4 and 0.5% glycerol) containing protease
inhibitors. Equal amounts of total protein (30–40 μg)
were separated by SDS-PAGE electrophoresis, transferred
to membranes and immunoblotted with the following
antibodies: mouse monoclonal anti-myc 9E10, mouse
monoclonal anti-alpha tubulin (Sigma Corporation, St.
Louis, Missouri, USA), mouse monoclonal anti-utrophin
(NOVOCASTRA, Newcastle, UK), rabbit polyclonal anti-
laminin (Sigma Corporation, St. Louis, Missouri, USA),
mouse monoclonal anti-beta-Actin (Sigma Corporation,
St. Louis, Missouri, USA), rabbit polyclonal anti-Sp1 (Santa
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protein level was performed using ImageJ analysis software.
Results and discussion
One central point in the designing of synthetic zinc finger
peptides is to increase their specificity toward the desired
DNA target [25,31]. The simplest approach for success is
to increase the length of the target sequence to decrease
its frequency in the genome. By assuming a random base
distribution, an 18-base-pair DNA target sequence is sta-
tistically predicted to be unique in the haploid human
genome. We chose the following DNA target sequence:
50- GCT GCT GCG GGC TGG GAG- 30, that is present
only once in both human and mouse genomes, in the
utrophin gene promoter “A” (Figure 1A). In order to tar-
get this 18-base-pair DNA sequence we designed and
constructed a novel artificial gene named “UtroUp” con-
taining six zinc finger domains in a tandem array. To be
able to test the therapeutic potential of our artificial
transcription factor in a dystrophic mouse model (mdx),
we chose a DNA target sequence in a region that was
completely conserved in both the human and the mouse
utrophin promoter “A” (Figure 1A). This region is
located near several natural transcription factor DNA-Figure 1 A graphical representation of the human and mouse utroph
UtroUp peptide (GenBank JQ073900). A: On the left is shown an alignm
“A”. The UtroUp DNA target sequence, which is 18 base pairs long, is unde
and mice. On the right is shown the 18-base-pair UtroUp DNA target sequ
italics. B: The amino acid sequence of the synthetic six zinc finger DNA-bin
tandem array is underlined and numbered. The amino acid residues in the
are indicated in bold. The zinc finger domains 4, 5 and 6 are inherited by t
produced UtroUp peptide fused to glutathione S-transferase (GST).binding sites in a chromatin-accessible region [18].
UtroUp, with its six zinc finger domains, is an extended
version of the previously engineered three zinc finger
transcription factor Jazz [18,20-22]. At its 50 end, the
UtroUp DNA target sequence comprises 9 base pairs of
the DNA target sequence of Jazz, as indicated in italics
in Figure 1A (right side). Figure 1B shows the amino
acid sequence of the UtroUp peptide. The first three
UtroUp zinc fingers have been newly designed, engi-
neered and selected, while the last three are coincident
with the previously engineered Jazz zinc finger domains.
The amino acids responsible for the specific nucleotide
contact in each zinc finger (alpha helix, positions −1, +3
and +6) have been chosen on the basis of the available
“recognition code” that combines the zinc finger primary
structure and potential DNA-binding sites [18,24,28-30].
We have generated UtroUp by coupling the available
recognition code with DNA binding performance selec-
tion evaluated by EMSA [18]. It is important to note
that the zinc finger peptide binds the DNA target se-
quence in an anti-parallel manner. To test the UtroUp
DNA-binding ability, we produced and purified UtroUp,
which was fused to a glutathione S-transferase (GST) do-
main (GST-UtroUp), in bacteria (Figure 1C). The affinity/in promoters and the amino acid sequences of the six zinc finger
ent of DNA sequences of the human and mouse utrophin promoter
rlined. The DNA target sequence is 100% conserved between humans
ence. The portion of the Jazz DNA target sequence is indicated in
ding domain of the UtroUp peptide. Each zinc finger domain in the
α-helix (−1, +3 and +6), which are key for the DNA-binding specificity,
he Jazz peptide. C: A schematic representation of the bacterially
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sequence was evaluated by electrophoretic mobility shift
assays (EMSA).
As shown in Figure 2A a marked shift is observed when
GST-UtroUp is incubated with the wild type (WT) oligo-
nucleotide probe containing UtroUp DNA-binding site
(lane 2), while no shift is revealed in presence of the
“Scrambled” oligonucleotide probe (lane 4). Then, to test
the overall binding activity of UtroUp, we concentrated on
the DNA binding contribution of the two crucial central
zinc fingers 3 and 4. We compared, in an EMSA assay, in-
creasing amount of GST-UtroUp with either WT oligo-
nucleotide target or centrally mutated oligonucleotideFigure 2 The UtroUp DNA-binding affinity/specificity analysed by EM
incubated with an equal amount of either the labelled wild-type DNA targ
B: (Left) An increasing amount of the GST-UtroUp protein (20, 40, 80 nM) w
DNA target (lanes 1–4) or with the labelled mutant DNA target (lanes 5–8)
lowercase characters. (Right) Histogram shows a percentage of probes (WT
C: An equal amount (12 nM), of the GST-UtroUp protein (lane 2) and GST-J
UtroUp-Jazz DNA target. D: An EMSA prototype performed for the determi
UtroUp protein (1, 2, 3, 4, 8, 12, 30, and 60 nM) was complexed with the la
staining of purified/eluted GST-UtroUp and GST-Jazz fusion proteins compa
values of the GST-UtroUp/DNA-target and GST-Jazz/DNA complexes corres
concentration is expressed in nM.target. As shown in Figure 2B, a strong saturated shift sig-
nal is observed even at the lowest concentration of GST-
UtroUp protein in the presence of the wild type oligo-
nucleotide target (lanes 1–3), while the GST-UtroUp shift
appears dramatically compromised in the presence of six
base pairs mutated oligonucleotide DNA target (lanes 5–7)
(see quantification analysis, Figure 2, panel B right). Import-
antly, comparing GST-UtroUp and GST-Jazz performance
in the same EMSA, the DNA target shift in presence of
GST-UtroUp is clearly stronger than the shift obtained with
GST-Jazz (Figure 2C). Then, to measure the affinity of the
GST-UtroUp toward its DNA target sequence, the dissoci-
ation constant (Kd) was determined by EMSA performedSA. A: An equal amount of the GST-UtroUp protein (14 nM) was
et (lanes 1–2) or with the labelled scrambled DNA target (lanes 3–4).
as incubated with an equal amount of either the labelled wild-type
. The two mutated triplets in the DNA target are indicated by
and Mutated) shifted with increasing amounts of GST-UtroUp protein.
azz protein (lane 1) were incubated with an equal amount of labelled
nation of the dissociation constant (Kd). An increasing amount of GST-
belled UtroUp DNA target. E: (Top) Quality control by Coomassie blue
red with purified commercial bovine serum albumin. (Bottom) The Kd
pond approximately to 3,5 nM and 32 nM respectively. The protein
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bined with a constant amount of labelled UtroUp DNA
oligonucleotide target (Figure 2D). In our experimental
conditions, we obtained for UtroUp a Kd of approximately
3,5 nM (Figure 2E). The UtroUp Kd value is lower than
the Kd values measured for our artificial transcription fac-
tors that contain three or four zinc finger domains [18,19],
indicating a tighter binding of UtroUp to the DNA target
sequence. In particular, UtroUp Kd value is about ten-fold
lower than the Kd value of its progenitor Jazz (32nM), as
shown in the EMSA derived graph in Figure 2E. Based on
the encouraging UtroUp Kd data, we characterised the
biological activity of UtroUp in the human HeLa cell line,
as both a simple six zinc finger peptide (UtroUp) and as a
fusion with the strong “CJ7” activation domain, which
resulted in the CJ7-UtroUp molecule (Figure 3A) [21].
The CJ7 transcriptional activation domain was derivedFigure 3 The trans-activation of the human utrophin promoter “A”. A
mammalian expression vector. B: A graphical representation of the human
region of the human utrophin promoter “A” containing the 18-base-pair U
underlined characters) that was cloned upstream of the reporter gene (Luc
Luc utrophin promoter “A” construct or the control reporter pGL2-Promote
region-only UtroUp, or the CJ7-UtroUp or the CJ7-Jazz in HeLa cells. The d
experiments that were performed in triplicate. (Rigth) Western blot analysis
construct and the indicated CJ7-UtroUp or CJ7-Jazz expression vectors. The
anti-alpha tubulin antibody.from the regulatory multivalent adaptor Che-1/AATF [32-
34]. The CJ7 domain is 100 amino acids in size, and it is a
stronger activator than the canonical herpes simplex virus-
derived Vp16 activation domain [21]. We previously
showed that the CJ7 domain in fusion with the synthetic
three zinc finger Jazz protein efficiently promotes tran-
scription and the accumulation of the acetylated form of
histone H3 on the genomic utrophin promoter locus [21].
To evaluate the relative transcriptional activity of the CJ7-
UtroUp and the CJ7-Jazz artificial transcription factors
[21], we separately transfected, into HeLa cells, the con-
structs expressing the two molecules and the construct
expressing only the UtroUp zinc finger DNA binding do-
main (as a control) together with the luciferase reporter
construct pXP-Luc [35], which contained the utrophin
promoter “A” region including the 18-base-pair UtroUp
target sequence (Figure 3B).: Schematic representation of the CJ7-UtroUp chimera in the
utrophin promoter “A”. The pXP-Luc construct consists of a minimal
troUp target DNA-binding sequence (indicated in italicised and
iferase). C: (Left) A histogram shows the fold of induction of the pXP-
r (Promega) that was obtained upon co-transfection with the finger
ata are presented as the means ± S.D. of three independent
cell lysates from HeLa cells transiently cotransfected with pXP-Luc
membrane was incubated with the anti-myc tag antibody and the
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the luciferase activity revealed a ten to eleven fold induc-
tion of the pXP-Luc construct in the presence of CJ7-
UtroUp. This strong activation appears to be highly spe-
cific, and it is even stronger than the activation obtained
using the prototype CJ7-Jazz [21], taking into account a
comparable expression of CJ7-UtroUp and CJ7-Jazz pro-
teins, as shown in the western blot (Figure 3C). To verify
whether the six zinc finger protein CJ7-UtroUp accesses
the utrophin promoter locus in the chromatin infra-
structure, we performed chromatin immunoprecipitationFigure 4 The binding and upregulation of the endogenous utrophin
(with either an empty control vector or with the CJ7-UtroUp expression ve
The immunoprecipitates from each sample were analysed by PCR perform
of the promoters of the unrelated thymidine kinase and dystrophin genes
included as controls. A sample representing the linear amplification of the
shows quantification of ChIP-PCR bands presented as fraction of the input.
UtroUp expression vector or with an empty control vector) using anti-acety
Immunoprecipitates from each sample were analyzed by PCR performed u
by real-time PCR of the utrophin gene mRNA expression in HeLa cells tran
utrophin and GAPDH gene expression is shown as means ± S.D. from thre
Western blot analysis of total protein lysates from HeLa cells transfected wi
vector. The membrane was incubated with the indicated antibodies. (Right
densitometric analysis.experiments (ChIPs). As shown in Figure 4A, ChIP
experiments demonstrated that CJ7-UtroUp accesses the
genomic utrophin promoter A locus in an efficient way.
To verify CJ7-UtroUp specificity toward the genomic utro-
phin promoter locus, we tested in the same ChIP experi-
ments unrelated gene-promoters and potential UtroUp
genomic “off-target” sites. A BLAST search indicated that
the 18 base pairs UtroUp target sequence is present only
once in both human and mouse genomes. As expected, the
BLAST search pointed out several potential chromosomal
off-target sites containing a number of nucleotidegene. A: (Left) The ChIP assay was performed in transfected HeLa cells
ctor) using myc-tag monoclonal antibody/protein G-agarose beads.
ed using primers specific for the human utrophin promoter “A”. PCRs
and PCRs of specific regions on the chromosomes 16 and 17 were
total input chromatin (input) was included (lane 1). (Right) Histogram
B: ChIP was performed in transfected HeLa cells (with either the CJ7-
lated histone H3 rabbit polyclonal antibody/protein G-agarose beads.
sing primers specific for human utrophin promoter “A”. C: The analysis
sfected with the CJ7-UtroUp or control vectors. The ratio between the
e independent experiments that were performed in triplicate. D: (Left)
th either empty vector (Control) or with the CJ7-UtroUp expression
) Histogram shows utrophin expression evaluated by
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quence. In particular, we tested two potential off-target
sites present in loci on human chromosome 16 and
chromosome 17, carrying 15 base pair matches out of 18
and 16 base pair matches out of 18 respectively (see mater-
ial and method section). A quantification analysis of all
ChIP/PCR bands is reported in Figure 4A (right side). All
these ChIP data taken together indicate a high specificity
of CJ7-UtroUp protein toward its DNA target in the utro-
phin promoter A. Moreover as shown in Figure 4B a ChIP
assay demonstrated that CJ7-UtroUp is able to promote
accumulation of the acetylated form of histone H3. Hyper-
acetylation correlates with transcriptional activation and
indicates that histone-modifying activities [36,37] could
contribute to the transcriptional control induced by CJ7-
UtroUp. Next, we determined the level of endogenous
utrophin upregulation that was induced by the expression
of CJ7-UtroUp. To this end, we performed a quantitative
analysis of the utrophin mRNA levels using real-time
PCR. As shown in Figure 4C, we observed an approxi-
mate 2.0-fold increase in utrophin transcription level in
the presence of CJ7-UtroUp compared to the control
sample. Additionally, to determine whether the changes
in the utrophin mRNA expression levels, which were
induced by the presence of CJ7-UtroUp, were consistent
with changes in the utrophin protein level, we performed
western blot analysis using an anti-utrophin antibody. As
shown in Figure 4D, we observed a perfect correlation be-
tween the upregulation of the utrophin mRNA and the
utrophin protein. In addition, CJ7-UtroUp appears to
mimic the natural transcriptional regulatory mechanisms,
which give rise to an increase in all of the different utro-
phin isoforms, as shown by the utrophin protein pattern
in western blot.
The synthetic transcription factor Jazz [18], with its
three zinc finger domains, binds a 9-base-pair DNA se-
quence. Bagly [19], the first Jazz variation, has four zinc
finger domains and binds a 12-base-pair DNA sequence.
As described here, UtroUp, with its six zinc finger
domains, binds an 18-base-pair DNA sequence. Notably,
a 9-base-pair DNA sequence is statistically present in the
human genome (≅ 3.5 × 109 bp) approximately 1.3 × 104
times, a 12-base-pair sequence is present 210 times and
an 18-base-pair sequence is present only once [31]. More-
over, when fused with our strong activation domain CJ7,
UtroUp specifically and efficiently upregulates the utro-
phin gene expression.
Conclusions
In an attempt to improve the efficacy of our artificial tran-
scription factors, engineered to reprogram the expression
of the utrophin gene, we focused on tuning both DNA-
binding affinity/specificity and transcriptional perfor-
mances. Our novel artificial transcription factor, CJ7-UtroUp, represents a good compromise between small
size, high DNA target affinity/specificity and efficient tran-
scriptional activation. The small size makes UtroUp par-
ticular suitable for viral vector delivery and the possibility
of targeting a unique site in the genome extremely
reduces off-target effects on global transcription. UtroUp
and its upcoming variations may represent an important
platform for the development of future applications in the
DMD gene therapy field. Moreover, human myogenic cell
lines and mouse models expressing UtroUp can offer an
unique model system for screening novel compounds that
are able to upregulate the utrophin gene for DMD
treatment.
Importantly, our results contribute to demonstrate that
artificial zinc finger transcription factors may be a class
of therapeutic reagents for treatment of crucial inherited
diseases [38].
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